Jubilant Pharmova Ltd (JUBLPHARMA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Jubilant Pharmova Ltd on NSE and BSE, with an AI summary of each filing.
Earning Webinar
Intimation · 16 Nov 2026, 8:30 am
Jubilant Pharmova Schedules Q2 and H1 FY27 Earnings Webinar Jubilant Pharmova Limited will host an earnings webinar for all investors on 16th Nov'26 from 08:30 AM to 09:30 AM IST via Zoom to discuss its financial performance for the quarter and half year ended 30th Sep'26 (Q2 & H1 FY27). The session will include management commentary followed by an interactive Q&A. Pre-registration is mandatory up to three hours prior to the call, and the investor presentation will be submitted to stock exchanges and published on the company's website ahead of the event.
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 13 Nov 2026, 5:30 am
JUBILANT PHARMOVA LIMITED has informed the Exchange about Board Meeting to be held on 13-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 13 Nov 2026, 5:30 am
Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2026 ,inter alia, to consider and approve Unaudited standalone and ....
Intimation · 13 Nov 2026, 5:30 am
Jubilant Pharmova Board to Consider Q2 Results on 13th Nov'26 Jubilant Pharmova Limited announced that its Board of Directors is scheduled to meet on 13th Nov'26. The board will inter-alia consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26, pursuant to Regulation 29 of SEBI LODR Regulations.
Credit Rating
Others (Uncategorized) · 21 Oct 2026, 9:56 pm
India Ratings Assigns IND AA+/Stable to Jubilant Pharmova's ₹1,400 Crore NCDs India Ratings and Research has assigned an 'IND AA+/Stable' credit rating to Jubilant Pharmova Limited's proposed Non-Convertible Debentures (NCDs) amounting to ₹1,400.00 crore (INR 14,000 million). The rating communication was formally received by the company on 21st Oct'26 at 11:47 AM IST. This high-grade credit rating with a stable outlook reflects the agency's assessment of the issuer's robust credit profile and financial stability for its proposed long-term debt issuance.
Announcement under Regulation 30 - Credit Rating
Others (Uncategorized) · 14 Oct 2026, 10:01 pm
Jubilant Pharmova Receives ICRA AA+ Stable Rating for Rs 1,400 Crore NCDs ICRA Limited assigned an [ICRA]AA+ rating with a Stable outlook to Jubilant Pharmova Limited's proposed Non-Convertible Debenture (NCD) programme amounting to Rs 1,400.00 crore. The rating communication was received by the company on 13th Oct'26. The assigned credit rating remains valid throughout the life of the instrument once issued, reflecting strong creditworthiness for the company's planned debt issuance.
Issue of Secured / Unsecured, Listed, Rated, Redeemable Non-Convertible Debentures on Private Placement Basis
Others (Uncategorized) · 12 Oct 2026, 6:08 pm
Jubilant Pharmova Approves NCD Issuance of up to ₹800 Crore Jubilant Pharmova's Board approved the issuance of up to 80,000 listed, rated, redeemable Non-Convertible Debentures (NCDs) of face value ₹1,00,000 each, aggregating up to ₹800 crore on a private placement basis in one or more tranches on 12th Oct'26. The NCDs carry a tenure of up to five years and will be listed on BSE. Additionally, the Board is seeking shareholder approval via Postal Ballot to issue non-convertible debt securities up to ₹2,500 crore over a one-year period.
Issuance of Secured / Unsecured, Listed, Rated, Redeemable Non-Convertible Debentures (NCDs) on Private Placement Basis
Outcome · 12 Oct 2026, 6:05 pm
Jubilant Pharmova Board Approves ₹800 Crore NCD Issuance and ₹2,500 Crore Borrowing Limit Jubilant Pharmova's board approved the private placement of up to 80,000 listed, rated, redeemable NCDs (face value ₹1,00,000 each) aggregating up to ₹800 crore across multiple tranches with a tenure of up to five years, to be listed on BSE. Additionally, the board is seeking shareholder approval via postal ballot to issue non-convertible debt securities on a private placement basis for an aggregate outstanding amount of up to ₹2,500 crore over a one-year period. Coupon rates will be determined via bidding.
Intimation under regulation 30
Others (Uncategorized) · 09 Oct 2026, 2:53 am
Jubilant Pharmova Invests CAD 94.5M to Double RUBY-FILL Production Capacity Jubilant Draximage Inc., a step-down subsidiary of Jubilant Pharmova, announced an investment of CAD 94.5 million on 8th Oct'26 to modernize and expand its Kirkland, Québec facility. The capex will double the manufacturing capacity of its flagship cardiac PET imaging product, RUBY-FILL®, addressing a customer base that doubled over the last three years. The project is backed by CAD 23.8 million in financial support from the Government of Canada via the Strategic Response Fund's innovation funding stream.
JUBILANT PHARMOVA LIMITED has informed the Exchange about Board Meeting to be held on 12-Oct-2026 to consider Fund raising.
Intimation · 08 Oct 2026, 1:17 am
To consider and approve raising of funds through the issuance of Non-Convertible Debentures (NCDs) and/or such other securities as may be permitted under applicable laws, and to approve seeking shareholders' approval, as may be required
Intimation · 08 Oct 2026, 1:16 am
Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/10/2026 ,inter alia, to consider and approve To consider and approve raising ....
Intimation · 08 Oct 2026, 1:13 am
Jubilant Pharmova Board to Consider Fundraising via NCDs on 12th Oct'26 Jubilant Pharmova Limited has scheduled a Board of Directors meeting on Monday, 12th Oct'26, to consider and approve fundraising via the issuance of Non-Convertible Debentures (NCDs) or other permissible securities under applicable laws. The Board will also evaluate seeking necessary shareholder approvals for the proposed capital-raising initiative.
Specimen letter sent to shareholders for withheld of dividend for FY 2025-26
Dividend · 29 Sept 2026, 12:16 am
Jubilant Pharmova Withholds FY26 Final Dividend for Non-KYC Compliant Shareholders Jubilant Pharmova has issued intimations to physical shareholders whose FY26 final dividend has been withheld due to incomplete KYC and bank details, following SEBI mandates requiring electronic-only dividend disbursements. Affected investors holding shares as of the 24th Jul'26 record date must submit standard KYC documentation, including Forms ISR-1, ISR-2, and nomination forms (SH-13 or ISR-3), to registrar Alankit Assignments. Dividend payouts will be remitted electronically once shareholder records and banking credentials are authenticated and validated.
Update on USFDA Spokane
Others (Uncategorized) · 12 Sept 2026, 1:12 am
USFDA Classifies Jubilant HollisterStier Spokane CMO Facility as VAI Jubilant Pharmova announced that the USFDA concluded its review of the Establishment Inspection Report for the inspection conducted between 8th Jun'26 and 17th Jun'26 at Jubilant HollisterStier LLC's CMO facility in Spokane, Washington, USA. The regulator classified the sterile injectable and ophthalmic manufacturing site as Voluntary Action Indicated (VAI), successfully concluding the regulatory inspection review without major compliance hurdles.
Receipt of Show Cause Notice by Jubilant Pharmova Limited - GST
Others (Uncategorized) · 01 Sept 2026, 6:12 pm
Jubilant Pharmova Receives GST Show Cause Notice Totaling Rs. 87.31 Crore Jubilant Pharmova received a Show Cause Notice on 31 Aug'26 from the Assistant Commissioner of Commercial Taxes, Mysore, for FY23. The notice proposes a total demand of Rs. 87.31 Cr, comprising Rs. 33.58 Cr in GST, Rs. 20.15 Cr in interest, and a Rs. 33.58 Cr penalty. Issues cited include alleged ineligible/excess ITC and differential tax. The company asserts the notice is legally incorrect, plans to contest it, has a strong case, and expects no financial or operational impact.
Receipt of Show Cause Notice - Jubilant Generics Limited
Others (Uncategorized) · 28 Aug 2026, 3:38 pm
Jubilant Pharmova Subsidiary Receives GST Show Cause Notice for Rs. 105.5 Cr Jubilant Generics, a subsidiary, received a GST Show Cause Notice on 27 Aug'26 for FY21-FY22. The notice proposes a demand for an alleged inadmissible IGST refund of Rs. 52.75 Cr, plus an equal penalty of Rs. 52.75 Cr and unquantified interest, totaling over Rs. 105.5 Cr. The company disputes the claim, stating the notice is legally incorrect and was issued without proper verification. Management believes it has a strong case and expects no financial or operational impact, intending to file a detailed reply.
Scrutinizer''s Report
Annual General Meeting · 27 Aug 2026, 1:37 am
Jubilant Pharmova FY26 Results: Strong Revenue Growth and Positive Q1 FY27 Start In FY26, Jubilant Pharmova's consolidated revenue grew 14% to ₹83 billion, with EBITDA up 8% to ₹13 billion. Normalised PAT increased 7% to ₹4 billion. The Net Debt-to-EBITDA ratio rose to 1.3x from 1.1x. Key growth drivers included CDMO Sterile Injectables (revenue +38%), CRDMO (revenue +15%), and Generics (revenue +13%). For Q1 FY27, revenue rose 17% YoY to ₹22 billion, though EBITDA at ₹2.7 billion was impacted by temporary issues. The Board recommended a dividend of ₹5 per share.
Outcome of AGM
Annual General Meeting · 27 Aug 2026, 1:35 am
USFDA Approval for Line 3, Contract manufacturing facility, Spokane, USA
Others (Uncategorized) · 23 Aug 2026, 6:09 am
Jubilant Pharmova Gets USFDA Nod for Spokane CMO Facility Jubilant Pharmova announced on Aug 23, '26, that it received USFDA approval for its subsidiary Jubilant HollisterStier's contract manufacturing facility in Spokane, USA. The approval allows commercial batch manufacturing of the first product on the new Line 3, an isolator-based fill and finish line. This development positively impacts the company's sterile injectable contract manufacturing business by validating its new capacity and enabling revenue generation from this line. The approval was received on Aug 21, '26 (PST).
Press Release and presentation
Press Release · 11 Aug 2026, 12:52 am
Un-audited Financial Results for the Quarter ended June 30, 2026
Financial Result · 11 Aug 2026, 12:47 am
Jubilant Pharmova Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Million) ■ Revenue: 22,294 (+17.3% YoY | -2.6% QoQ) ■ EBITDA: 2,480 (-14.4% YoY | -26.9% QoQ) ■ EBITDA Margin (%): 11.1 (-411 bps YoY | -369 bps QoQ) ■ PAT: 565 (-45.1% YoY | -52.7% QoQ) ■ EPS (INR): 3.56 (-45.0% YoY | -52.7% QoQ) Jubilant Pharmova Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Million) Segmental Performance Radiopharma ■ Revenue: 10,221 (+17.7% YoY | +3.2% QoQ) ■ EBIT: 780 (-20.9% YoY | +0.3% QoQ) ■ EBIT Margin (%): 7.6 (-372 bps YoY | -23 bps QoQ) Allergy Immunotherapy ■ Revenue: 2,144 (+12.0% YoY | -1.5% QoQ) ■ EBIT: 635 (+3.6% YoY | -29.3% QoQ) ■ EBIT Margin (%): 29.6 (-241 bps YoY | -1165 bps QoQ) Contract Development and Manufacturing Organisation - Sterile Injectables ■ Revenue: 5,198 (+32.4% YoY | -4.9% QoQ) ■ EBIT: 73.0 (-83.1% YoY | -86.9% QoQ) ■ EBIT Margin (%): 1.4 (-957 bps YoY | -882 bps QoQ) Contract Research, Development and Manufacturing Organisation ■ Revenue: 3,258 (+4.6% YoY | -2.7% QoQ) ■ EBIT: 356 (+31.9% YoY | -1.1% QoQ) ■ EBIT Margin (%): 10.9 (+226 bps YoY | +17 bps QoQ) Generics ■ Revenue: 1,734 (+4.5% YoY | -19.1% QoQ) ■ EBIT: -101 (-2425.0% YoY | Profit to Loss QoQ) ■ EBIT Margin (%): -5.8 (-558 bps YoY | Profit to Loss QoQ) Proprietary Novel Drugs ■ Revenue: 0.0 ■ EBIT: -76.0 (-22.6% YoY | -2.7% QoQ) ■ EBIT Margin (%): 0.0
outcome of Board meeting
Outcome · 11 Aug 2026, 12:44 am
Investors/ Analysts Meeting
Intimation · 05 Aug 2026, 10:27 pm
Jubilant Pharmova to Meet Institutional Investors on Aug 13-14 Jubilant Pharmova management will conduct physical meetings with institutional investors in Mumbai from 13 Aug'26 to 14 Aug'26. The meetings are part of the Emkay Confluence conference organized by Emkay Global Financial Services. Key attendees include HDFC AMC, ICICI Prudential AMC, Motilal Oswal AMC, and Tata Asset Management. Discussions will focus on the Q1'FY27 earnings presentation, which is scheduled to be released on 10 Aug'26 post-disclosure of financial results. Meeting schedules remain subject to change.
Newspaper advertisements titled ''Notice of 48th Annual General Meeting, E-voting, Record Date and Final Dividend Information''
Annual General Meeting · 03 Aug 2026, 4:34 am
Intimation to shareholders about deduction of tax at source (TDS) on Final Dividend for FY 2026-26, if approved by the members at the ensuing AGM
Annual General Meeting · 02 Aug 2026, 4:26 am